

# Edward A Neuwelt

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5592400/edward-a-neuwelt-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

10,448  
citations

54  
h-index

99  
g-index

165  
ext. papers

11,580  
ext. citations

5  
avg, IF

5.83  
L-index

#	Paper	IF	Citations
154	Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5034-43	2.2	575
153	Engaging neuroscience to advance translational research in brain barrier biology. <i>Nature Reviews Neuroscience</i> , <b>2011</b> , 12, 169-82	13.5	418
152	Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2010</b> , 30, 15-35	7.3	374
151	Strategies to advance translational research into brain barriers. <i>Lancet Neurology</i> , <b>2008</b> , 7, 84-96	24.1	370
150	Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8588-96	2.2	355
149	Chemotherapy delivery issues in central nervous system malignancy: a reality check. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2295-305	2.2	316
148	Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. <i>Cancer</i> , <b>2000</b> , 88, 637-47	6.4	302
147	Mechanisms of disease: the blood-brain barrier. <i>Neurosurgery</i> , <b>2004</b> , 54, 131-40; discussion 141-2	3.2	238
146	Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. <i>Ophthalmology</i> , <b>2002</b> , 109, 1709-16	7.3	235
145	Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2408-17	2.2	229
144	Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? <i>Kidney International</i> , <b>2009</b> , 75, 465-74	9.9	200
143	Immunologic privilege in the central nervous system and the blood-brain barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 13-21	7.3	188
142	Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3503-9	2.2	184
141	Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 314, 1052-8	4.7	169
140	Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. <i>Kidney International</i> , <b>2017</b> , 92, 47-66	9.9	168
139	Imaging, Distribution, and Toxicity of Superparamagnetic Iron Oxide Magnetic Resonance Nanoparticles in the Rat Brain and Intracerebral Tumor. <i>Neurosurgery</i> , <b>2005</b> , 57, 785-796	3.2	166
138	The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 312, 424-31	4.7	160

137	Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. <i>Neurosurgery</i> , <b>2000</b> , 46, 51-61	3.2	160
136	Delivery of Virus-sized Iron Oxide Particles to Rodent CNS Neurons. <i>Neurosurgery</i> , <b>1994</b> , 34, 777-784	3.2	158
135	The Translational Significance of the Neurovascular Unit. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 762-770	3.4	156
134	Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1190-5	2.2	150
133	The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. <i>Neurosurgery</i> , <b>2007</b> , 60, 601-11; discussion 611-2	3.2	147
132	Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. <i>Radiology</i> , <b>2013</b> , 266, 842-52	20.5	133
131	Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2376-2385	59.2	127
130	Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 514-23	4	120
129	Delivery of virus-sized iron oxide particles to rodent CNS neurons. <i>Neurosurgery</i> , <b>1994</b> , 34, 777-84	3.2	113
128	Developments in the diagnosis and treatment of primary CNS lymphoma. A prospective series. <i>Cancer</i> , <b>1986</b> , 58, 1609-20	6.4	111
127	Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. <i>American Journal of Neuroradiology</i> , <b>2002</b> , 23, 510-9	4.4	111
126	Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuropathological studies. <i>Annals of Neurology</i> , <b>1983</b> , 14, 316-24	9.4	108
125	Cognitive Outcomes and Long-term Follow-up Results after Enhanced Chemotherapy Delivery for Primary Central Nervous System Lymphoma. <i>Neurosurgery</i> , <b>2000</b> , 51-61	3.2	108
124	Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. <i>Neurology</i> , <b>2013</b> , 81, 84-92	6.5	103
123	Increasing Volume of Distribution to the Brain with Interstitial Infusion: Dose, Rather Than Convection, Might Be the Most Important Factor. <i>Neurosurgery</i> , <b>1996</b> , 38, 746-754	3.2	101
122	Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 63-74	21.7	99
121	Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. <i>Hearing Research</i> , <b>2004</b> , 193, 25-30	3.9	98
120	Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. <i>Neurosurgery</i> , <b>1998</b> , 43, 879-86; discussion 886-9	3.2	96

119	Successful treatment of primary central nervous system lymphomas with chemotherapy after osmotic blood-brain barrier opening. <i>Neurosurgery</i> , <b>1983</b> , 12, 662-71	3.2	93
118	Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. <i>Neurosurgery</i> , <b>1995</b> , 37, 17-27; discussion 27-8	3.2	92
117	Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. <i>Blood</i> , <b>2008</b> , 111, 1085-93	3.3	89
116	Macrophage imaging within human cerebral aneurysms wall using ferumoxytol-enhanced MRI: a pilot study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2012</b> , 32, 1032-8	9.4	88
115	Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 235-41	3.5	80
114	High-resolution steady-state cerebral blood volume maps in patients with central nervous system neoplasms using ferumoxytol, a superparamagnetic iron oxide nanoparticle. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2013</b> , 33, 780-6	7.3	79
113	TR-15 USE OF IV N-ACETYL-CYSTEINE IN COMBINATION WITH SODIUM THIOSULFATE FOR PREVENTION OF OTOTOXICITY IN PEDIATRIC PATIENTS. <i>Neuro-Oncology</i> , <b>2015</b> , 17, iii40-iii40	1	78
112	Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. <i>Neuro-Oncology</i> , <b>2014</b> , 16, 1146-54	1	74
111	The paradoxical effect of bevacizumab in the therapy of malignant gliomas. <i>Neurology</i> , <b>2011</b> , 76, 87-93	6.5	73
110	Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. <i>Neurosurgery</i> , <b>2005</b> , 57, 785-96; discussion 785-96	3.2	72
109	Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2009</b> , 29, 853-60	7.3	70
108	Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. <i>Neurosurgery</i> , <b>1980</b> , 7, 36-43	3.2	67
107	MRI using ferumoxytol improves the visualization of central nervous system vascular malformations. <i>Stroke</i> , <b>2011</b> , 42, 1581-8	6.7	62
106	Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. <i>Neurosurgery</i> , <b>2001</b> , 48, 1033-40; discussion 1040-1	3.2	60
105	Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances. <i>Advances in Pharmacology</i> , <b>2014</b> , 71, 203-43	5.7	59
104	Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. <i>Investigative Radiology</i> , <b>2016</b> , 51, 221-227	10.1	59
103	In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging. <i>American Journal of Physiology - Cell Physiology</i> , <b>2007</b> , 293, C1698-708	5.4	57
102	An exploratory study of ferumoxtran-10 nanoparticles as a blood-brain barrier imaging agent targeting phagocytic cells in CNS inflammatory lesions. <i>American Journal of Neuroradiology</i> , <b>2005</b> , 26, 2290-300	4.4	55

101	Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. <i>American Journal of Roentgenology</i> , <b>2011</b> , 197, 981-8	5.4	53
100	Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. <i>Neurosurgery</i> , <b>2000</b> , 46, 704-9	3.2	51
99	Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. <i>Pituitary</i> , <b>2011</b> , 14, 80-91	4.3	50
98	Current status and future of relapsed primary central nervous system lymphoma (PCNSL). <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 627-33	1.9	50
97	Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. <i>Neurology</i> , <b>2013</b> , 81, 256-63	6.5	49
96	Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2004</b> , 309, 594-9	4.7	48
95	Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 440-445	2.2	47
94	The Influence of Anesthetic Choice, PaCO <sub>2</sub> , and Other Factors on Osmotic Blood-Brain Barrier Disruption in Rats with Brain Tumor Xenografts. <i>Anesthesia and Analgesia</i> , <b>1999</b> , 88, 559-567	3.9	47
93	Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. <i>Cancer</i> , <b>2008</b> , 112, 581-8	6.4	45
92	The influence of anesthetic choice, PaCO <sub>2</sub> , and other factors on osmotic blood-brain barrier disruption in rats with brain tumor xenografts. <i>Anesthesia and Analgesia</i> , <b>1999</b> , 88, 559-67	3.9	45
91	Magnetic resonance imaging of intracranial tumors: intra-patient comparison of gadoteridol and ferumoxytol. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 251-60	1	43
90	Atypical central nervous system lymphoma at the cranial base: report of four cases. <i>Neurosurgery</i> , <b>1998</b> , 43, 613-5; discussion 615-6	3.2	42
89	Targeting $\alpha$ -integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 110, 27-36	4.8	41
88	Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation. <i>Translational Stroke Research</i> , <b>2012</b> , 3, 166-73	7.8	41
87	Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol. <i>Radiology</i> , <b>2011</b> , 261, 796-804	20.5	41
86	Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. <i>Pediatric Blood and Cancer</i> , <b>2006</b> , 47, 174-82	3	41
85	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. <i>Neuro-Oncology</i> , <b>2015</b> , 17, 639-51	1	40
84	Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. <i>Neoplasia</i> , <b>2009</b> , 11, 187-95	6.4	39

83	Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 533-40	12.9	38
82	The Effects of Anesthesia on Osmotic Blood-Brain Barrier Disruption. <i>Neurosurgery</i> , <b>1990</b> , 26, 268-277	3.2	38
81	Inhibition of SUR1 decreases the vascular permeability of cerebral metastases. <i>Neoplasia</i> , <b>2013</b> , 15, 535-43	4.4	37
80	Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. <i>American Journal of Neuroradiology</i> , <b>2005</b> , 26, 258-65	4.4	37
79	Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. <i>Neurosurgery</i> , <b>2010</b> , 66, 48-58; discussion 58	3.2	37
78	Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , <b>2012</b> , 109, 105-14	4.8	36
77	Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1712-20	1.9	36
76	What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. <i>American Journal of Neuroradiology</i> , <b>2017</b> , 38, 1297-1302	4.4	35
75	Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. <i>Neuro-Oncology</i> , <b>2011</b> , 13, 51-60	1	33
74	BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. <i>Journal of Neuro-Oncology</i> , <b>2003</b> , 65, 49-62	4.8	32
73	Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions. <i>Current Neurology and Neuroscience Reports</i> , <b>2002</b> , 2, 216-24	6.6	31
72	Critical need for international consensus on ototoxicity assessment criteria. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1630-2	2.2	30
71	Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. <i>Neuro-Oncology</i> , <b>2009</b> , 11, 142-50	1	29
70	Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2016</b> , 12, 1535-42	6	28
69	Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. <i>Neurosurgery</i> , <b>1992</b> , 30, 23-9	3.2	27
68	Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10. <i>American Journal of Neuroradiology</i> , <b>2005</b> , 26, 1084-8	4.4	27
67	N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models. <i>Journal of Neuro-Oncology</i> , <b>2015</b> , 121, 433-40	4.8	25
66	Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol. <i>Neurosurgery</i> , <b>2018</b> , 82, 770-780	3.2	25

65	Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. <i>CNS Oncology</i> , <b>2014</b> , 3, 389-400	4	25
64	Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. <i>Neoplasia</i> , <b>2009</b> , 11, 1003-11	6.4	25
63	Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2207-15	12.9	24
62	Implications of the blood-brain barrier in primary central nervous system lymphoma. <i>Neurosurgical Focus</i> , <b>2006</b> , 21, E11	4.2	23
61	N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase III trials. <i>Journal of Vascular and Interventional Radiology</i> , <b>2008</b> , 19, 309-18	2.4	22
60	Imaging brain tumors with ferumoxtran-10, a nanoparticle magnetic resonance contrast agent. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2005</b> , 2, 871-882		22
59	Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model. <i>Neurosurgery</i> , <b>2000</b> , 47, 199-207	3.2	22
58	Blood-Brain Barrier Disruption in the Treatment of Brain Tumors <b>1989</b> , 195-261		22
57	Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. <i>Fluids and Barriers of the CNS</i> , <b>2015</b> , 12, 5	7	21
56	Association of Total Dose Intensity of Chemotherapy in Primary Central Nervous System Lymphoma (Human Non-Acquired Immunodeficiency Syndrome) and Survival. <i>Neurosurgery</i> , <b>2001</b> , 48, 1033-1041	3.2	21
55	Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. <i>Neurosurgery</i> , <b>2010</b> , 67, 87-93	3.2	20
54	Evaluation of a program to prevent head and spinal cord injuries: a comparison between middle school and high school. <i>Neurosurgery</i> , <b>1992</b> , 31, 557-61; discussion 561-2	3.2	20
53	Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 515-518	1.9	18
52	Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4026-7	2.2	18
51	Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. <i>Neurosurgery</i> , <b>1997</b> , 40, 1034-40; discussion 1040-2	3.2	17
50	Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1702-9	12.9	17
49	Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. <i>Fluids and Barriers of the CNS</i> , <b>2017</b> , 14, 16	7	16
48	Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma. <i>Anticancer Research</i> , <b>2013</b> , 33, 2391-400	2.3	16

47	High $\alpha$ Integrin Level of Cancer Cells Is Associated with Development of Brain Metastasis in Athymic Rats. <i>Anticancer Research</i> , <b>2017</b> , 37, 4029-4040	2.3	16
46	Unexpected Neurotoxicity of Etoposide Phosphate Administered in Combination with Other Chemotherapeutic Agents after Blood-Brain Barrier Modification to Enhance Delivery, Using Propofol for General Anesthesia, in a Rat Model. <i>Neurosurgery</i> , <b>2000</b> , 47, 199-207	3.2	16
45	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , <b>2021</b> , 23, 1056-1071	1	16
44	Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2504-11	12.9	15
43	Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. <i>Neuro-Oncology</i> , <b>2009</b> , 11, 503-13	1	14
42	Intra-arterial administration improves temozolomide delivery and efficacy in a model of intracerebral metastasis, but has unexpected brain toxicity. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 126, 447-54	4.8	13
41	Interactions between $\alpha$ Integrin and HER2 and Their Role in the Invasive Phenotype of Breast Cancer Cells In Vitro and in Rat Brain. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131842	3.7	13
40	Increasing Volume of Distribution to the Brain with Interstitial Infusion: Dose, Rather Than Convection, Might Be the Most Important Factor. <i>Neurosurgery</i> , <b>1996</b> , 746-754	3.2	13
39	Ferumoxytol-enhanced MRI differentiation of meningioma from dural metastases: a pilot study with immunohistochemical observations. <i>Journal of Neuro-Oncology</i> , <b>2016</b> , 129, 301-9	4.8	13
38	Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression. <i>Neuro-Oncology</i> , <b>2019</b> , 21, 517-526	1	13
37	Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , <b>2011</b> , 103, 353-60	4.8	11
36	Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2001</b> , 51, 1045-9	4	11
35	Dose escalation study of intravenous and intra-arterial N-acetylcysteine for the prevention of oto- and nephrotoxicity of cisplatin with a contrast-induced nephropathy model in patients with renal insufficiency. <i>Fluids and Barriers of the CNS</i> , <b>2017</b> , 14, 26	7	9
34	Comprehensive Review of the ThinkFirst Injury Prevention Programs: A 30-Year Success Story for Organized Neurosurgery. <i>Neurosurgery</i> , <b>2017</b> , 81, 416-421	3.2	8
33	Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care. <i>Journal of Magnetic Resonance Imaging</i> , <b>2018</b> , 48, 441-448	5.6	8
32	Effect of Antigenic Heterogeneity on the Efficacy of Enhanced Delivery of Antibody-targeted Chemotherapy in a Human Lung Cancer Intracerebral Xenograft Model in Rats. <i>Neurosurgery</i> , <b>2003</b> , 53, 1406-1413	3.2	8
31	Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	7
30	Quantitative comparison of delayed ferumoxytol T enhancement with immediate gadoteridol enhancement in high grade gliomas. <i>Magnetic Resonance in Medicine</i> , <b>2018</b> , 80, 224-230	4.4	7



29	The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma. <i>Journal of Neurosurgery: Pediatrics</i> , <b>2013</b> , 11, 60-7	2.1	6
28	Distinguishing Extravascular from Intravascular Ferumoxytol Pools within the Brain: Proof of Concept in Patients with Treated Glioblastoma. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 1193-1200	4.4	5
27	Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , <b>2020</b> , 147, 171-176	4.8	5
26	Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder. <i>Journal of NeuroVirology</i> , <b>2013</b> , 19, 601-5	3.9	5
25	Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab. <i>Fluids and Barriers of the CNS</i> , <b>2016</b> , 13, 23	7	4
24	SIOPEL 6: A multicenter open-label randomized phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard-risk hepatoblastoma (SR-HB).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS10094-TPS10094	2.2	3
23	Blood-Brain Barrier Disruption Chemotherapy <b>2006</b> , 262-273		2
22	The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 97-112		2
21	Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , <b>2020</b> , 51, S5-S12	1.4	2
20	Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. <i>Neuro-Oncology Advances</i> , <b>2020</b> , 2, vdaa093	0.9	2
19	The clinical heterogeneity of entirely nonenhancing CNS lymphoma: a case series. <i>CNS Oncology</i> , <b>2021</b> , 10, CNS67	4	2
18	Risk Factors and Disease Course for Blood-Brain Barrier Disruption-Associated Maculopathy. <i>JAMA Ophthalmology</i> , <b>2021</b> , 139, 143-149	3.9	2
17	Long-Term Outcomes of Intra-Arterial Chemotherapy for Progressive or Unresectable Pilocytic Astrocytomas: Case Studies. <i>Neurosurgery</i> , <b>2021</b> , 88, E336-E342	3.2	2
16	Blood-Brain Barrier Disruption Chemotherapy <b>2018</b> , 145-153		2
15	Pharmacokinetics of Drug Delivery Past the Blood-Brain Barrier <b>2019</b> , 57-72		1
14	Enhanced Delivery of Rituximab In Combination with Methotrexate-Based Blood-Brain Barrier Disruption for Patients with Newly Diagnosed Primary CNS Lymphoma.. <i>Blood</i> , <b>2010</b> , 116, 2792-2792	2.2	1
13	The treatment of brain metastasis from breast cancer, role of blood-brain barrier disruption and early experience with trastuzumab. <i>Therapy: Open Access in Clinical Medicine</i> , <b>2006</b> , 3, 97-112		1
12	Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size. <i>American Journal of Roentgenology</i> , <b>2020</b> , 215, 1436-1442	5.4	1

11	MBCL-48. HEARING CHEMOPROTECTION WITH SODIUM THIOSULFATE (STS) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH STANDARD RISK MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i127-i128	1	1
10	Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors <b>2000</b> , 88, 637		1
9	Advances in Intraarterial Chemotherapy Delivery Strategies and Blood-Brain Barrier Disruption.. <i>Neurosurgery Clinics of North America</i> , <b>2022</b> , 33, 219-223	4	0
8	BloodBrain Barrier Disruption <b>2019</b> , 193-208		
7	Pseudo-extravasation rate constant of dynamic susceptibility contrast-MRI determined from pharmacokinetic first principles. <i>NMR in Biomedicine</i> , <b>2017</b> , 30, e3797	4.4	
6	Local and global gene therapy in the central nervous system. <i>Behavioral and Brain Sciences</i> , <b>1995</b> , 18, 76-78	0.9	
5	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. <i>Blood</i> , <b>2020</b> , 136, 12-12	2.2	
4	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. <i>Blood</i> , <b>2004</b> , 104, 1372-1372	2.2	
3	Magnetic Resonance Imaging of Brain Tumors Using Iron Oxide Nanoparticles <b>2011</b> , 297-304		
2	Oligodendroglial Tumors: Intra-arterial Chemotherapy. <i>Tumors of the Central Nervous System</i> , <b>2014</b> , 15-22		
1	Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis.. <i>Neuro-Oncology Advances</i> , <b>2022</b> , 4, v027	0.9	